A month has gone by since the last earnings report for Aduro Biotech, Inc. . Shares have lost about 3.6% in that time frame, underperforming the market.
Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Aduro Loss Wider than Expected, Sales Miss in Fourth Quarter
Aduro reported fourth-quarter 2016 loss of $0.44 per share, wider than the Zacks Consensus Estimate of a loss of $0.38. The company had reported earnings of $0.04 per share in the year-ago quarter.
Quarterly revenues plunged 88.7% year over year to $3.9 million. The top-line deterioration was mainly due to the recognition of milestones and a portion of upfront fees from Janssen in 2015. Revenues were marginally below the Zacks Consensus Estimate of $4.0 million.
Research and development expenses declined 7.9% in the quarter to $20.9 million, mainly due to higher license fees paid in 2015.
General and administrative expenses were $8.0 million, down 9% year over year due to lower professional fees paid in 2016.
For the year, the company reported loss of $1.40 per share, which was wider than a loss of $0.88 reported in 2015. Revenues were $50.7 million, down 30.5% year over year.
How Have Estimates Been Moving Since Then?
Following the release, investors have witnessed an upward trend in fresh estimates. There has been one revision higher for the current quarter
VGM Scores
At this time, Aduro 's stock has a poor score of 'F' on both growth and momentum front. Following the exact same course, the stock was allocated also a grade of 'F' on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'F'. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate investors will probably be better served looking elsewhere.
Outlook
While estimates have been trending upward for the stock, the magnitude of this revision is net zero. Notably, the stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.
Image: Bigstock
Why Is Aduro (ADRO) Down 3.6% Since the Last Earnings Report?
A month has gone by since the last earnings report for Aduro Biotech, Inc. . Shares have lost about 3.6% in that time frame, underperforming the market.
Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Aduro Loss Wider than Expected, Sales Miss in Fourth Quarter
Aduro reported fourth-quarter 2016 loss of $0.44 per share, wider than the Zacks Consensus Estimate of a loss of $0.38. The company had reported earnings of $0.04 per share in the year-ago quarter.
Quarterly revenues plunged 88.7% year over year to $3.9 million. The top-line deterioration was mainly due to the recognition of milestones and a portion of upfront fees from Janssen in 2015. Revenues were marginally below the Zacks Consensus Estimate of $4.0 million.
Research and development expenses declined 7.9% in the quarter to $20.9 million, mainly due to higher license fees paid in 2015.
General and administrative expenses were $8.0 million, down 9% year over year due to lower professional fees paid in 2016.
For the year, the company reported loss of $1.40 per share, which was wider than a loss of $0.88 reported in 2015. Revenues were $50.7 million, down 30.5% year over year.
How Have Estimates Been Moving Since Then?
Following the release, investors have witnessed an upward trend in fresh estimates. There has been one revision higher for the current quarter
Aduro Biotech, Inc. Price and Consensus
Aduro Biotech, Inc. Price and Consensus | Aduro Biotech, Inc. Quote
VGM Scores
At this time, Aduro 's stock has a poor score of 'F' on both growth and momentum front. Following the exact same course, the stock was allocated also a grade of 'F' on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'F'. If you aren't focused on one strategy, this score is the one you should be interested in.
Our style scores indicate investors will probably be better served looking elsewhere.
Outlook
While estimates have been trending upward for the stock, the magnitude of this revision is net zero. Notably, the stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.